Vertex Pharmaceuticals (VRTX) stock price rose over 5% in pre-market trading, after the company's kidney disease drug povetacicept achieved primary endpoints in a Phase 3 clinical trial. The drug was acquired through a $4.9 billion acquisition and can reduce urinary protein by 52% in IgA nephropathy patients. Vertex plans to submit an application to the FDA by the end of March, and analysts expect the peak sales of its kidney disease product line could exceed $10 billion.